Diabetes Damage: New Hope at the Source
- An experimental compound has been found to limit cell death, reduce inflammation, and lessen organ damage associated with diabetes.
- Researchers at NYU Langone Health report that, in mouse studies, a drug candidate-RAGE406R-successfully prevented the interaction of two proteins, RAGE and DIAPH1.
- The research, featured as a cover story in Cell Chemical Biology, demonstrates that preventing DIAPH1 from binding to RAGE can reduce swelling in diabetic tissues and accelerate repair...
“`html
New Compound Shows Promise in Reducing Diabetic complications
Table of Contents
Overview
An experimental compound has been found to limit cell death, reduce inflammation, and lessen organ damage associated with diabetes.
Researchers at NYU Langone Health report that, in mouse studies, a drug candidate-RAGE406R-successfully prevented the interaction of two proteins, RAGE and DIAPH1. This interaction contributes to heart and kidney injury linked to diabetes and impedes wound healing.
Blocking the RAGE-DIAPH1 Interaction: A Breakthrough
The research, featured as a cover story in Cell Chemical Biology, demonstrates that preventing DIAPH1 from binding to RAGE can reduce swelling in diabetic tissues and accelerate repair processes. Testing in both human cells and mouse models showed significant reductions in both immediate and long-term complications associated with type 1 and type 2 diabetes. RAGE406R is a small molecule specifically designed to target the RAGE protein.
“There are currently no treatments that address the root causes of diabetic complications, and our work shows that RAGE406R can-not by lowering high blood sugar, but rather by blocking the intracellular action of RAGE,” stated co-senior study author Ann Marie Schmidt, MD, the Dr. Iven Young professor of Endocrinology at the NYU Grossman School of Medicine. “If confirmed by further testing in human trials, the compound could perhaps fill gaps in treatment, including the fact that most current drugs work only against Type 2 diabetes.”
Understanding RAGE and DIAPH1’s Role in diabetic Damage
RAGE (Receptor for Advanced Glycation End Products) is a receptor protein that responds to advanced glycation end products (AGEs). AGEs form when proteins or fats bind to sugars, a process accelerated in individuals with diabetes. AGEs accumulate in the bloodstream in people with diabetes and obesity, and also increase naturally with age.
The study revealed that RAGE406R competes with DIAPH1 for the binding site on RAGE. DIAPH1 is crucial for forming actin filaments, essential components of the cell’s internal structure. Researchers found that DIAPH1’s connection to the inner tail of RAGE intensifies diabetic complications by increasing the formation of actin structures.
The RAGE-DIAPH1 Pathway: A Visual Representation
[image depicting RAGE, DIAPH1, AGEs, and RAGE406R would be ideal here]
From Screening to RAGE406R: Development and Prior Research
Dr. Schmidt’s team previously screened a library of over 58,000 molecules to identify those that could interfere with the RAGE-DIAPH1 pathway. Their initial lead compound, RAGE229, did not meet the necessary safety standards for further development. RAGE406R represents a refined molecule with improved properties.
The team’s research builds upon a